Christina K Psomas1, Donald R Hoover2, Qiuhu Shi3, Todd T Brown4, David E Vance5, Susan Holman6, Michael W Plankey7, Phyllis C Tien8,9, Kathleen M Weber10, Michelle Floris-Moore11, Hector H Bolivar12, Elizabeth T Golub13, Marcia McDonnell Holstad14, Kendra K Radtke15, Bani Tamraz16, Kristine M Erlandson17, Leah H Rubin13,18, Anjali Sharma19. 1. Department of Infectious Diseases and Internal Medicine, European Hospital Marseille, Marseille, France. 2. Department of Statistics and Biostatistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, Piscataway, NJ. 3. Department of Epidemiology and Community Health, New York Medical College, Valhalla, NY. 4. Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, School of Medicine, Baltimore, MD. 5. School of Nursing, The University of Alabama at Birmingham, Birmingham, AL. 6. Department of Medicine/STAR Program, State University of New York Downstate Health Sciences University, Brooklyn, NY. 7. Department of Medicine, Georgetown University Medical Center, Washington, DC. 8. Department of VA Medical Center, San Fransisco, CA. 9. Department of Medicine, University of California San Francisco, San Francisco, CA. 10. Department of Medicine, Cook County Health/CORE Center and Hektoen Institute of Medicine, Chicago, IL. 11. University of North Carolina School of Medicine, Chapel Hill, NC. 12. Department of Medicine, University of Miami Health System, Miami, FL. 13. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 14. Emory School of Nursing, Atlanta, GA. 15. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco School of Pharmacy, San Francisco, CA. 16. University of California, San Francisco, School of Pharmacy, San Francisco, CA. 17. Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO. 18. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD; and. 19. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.
Abstract
BACKGROUND: Aging in people with HIV is associated with increased risk of developing synergistic conditions such as neurocognitive impairment, polypharmacy, and falls. We assessed associations between polypharmacy (use of 5 or more non-ART medications), use of neurocognitive adverse effects (NCAE) medications, and odds of falls in women with HIV (WWH) and without HIV (HIV-). METHODS: Self-reported falls and medication use data were contributed semiannually by 1872 (1315 WWH and 557 HIV-) Women's Interagency HIV Study participants between 2014 and 2016. Polypharmacy and NCAE medication use were evaluated separately and jointly in multivariable models to assess their independent contributions to single and multiple falls risk. RESULTS: The proportion of women who reported any fall was similar by HIV status (19%). WWH reported both greater polypharmacy (51% vs. 41%; P < 0.001) and NCAE medication use (44% vs. 37%; P = 0.01) than HIV- women. Polypharmacy conferred elevated odds of single fall [adjusted odds ratio (aOR) 1.67, 95% CI: 1.36 to 2.06; P < 0.001] and multiple falls (aOR 2.31, 95% CI: 1.83 to 2.93; P < 0.001); the results for NCAE medications and falls were similar. Both polypharmacy and number of NCAE medications remained strongly and independently associated with falls in multivariable models adjusted for HIV serostatus, study site, sociodemographics, clinical characteristics, and substance use. CONCLUSIONS: Polypharmacy and NCAE medication use were greater among WWH compared with HIV-, and both were independently and incrementally related to falls. Deprescribing and avoidance of medications with NCAEs may be an important consideration for reducing fall risk among WWH and sociodemographically similar women without HIV.
BACKGROUND: Aging in people with HIV is associated with increased risk of developing synergistic conditions such as neurocognitive impairment, polypharmacy, and falls. We assessed associations between polypharmacy (use of 5 or more non-ART medications), use of neurocognitive adverse effects (NCAE) medications, and odds of falls in women with HIV (WWH) and without HIV (HIV-). METHODS: Self-reported falls and medication use data were contributed semiannually by 1872 (1315 WWH and 557 HIV-) Women's Interagency HIV Study participants between 2014 and 2016. Polypharmacy and NCAE medication use were evaluated separately and jointly in multivariable models to assess their independent contributions to single and multiple falls risk. RESULTS: The proportion of women who reported any fall was similar by HIV status (19%). WWH reported both greater polypharmacy (51% vs. 41%; P < 0.001) and NCAE medication use (44% vs. 37%; P = 0.01) than HIV- women. Polypharmacy conferred elevated odds of single fall [adjusted odds ratio (aOR) 1.67, 95% CI: 1.36 to 2.06; P < 0.001] and multiple falls (aOR 2.31, 95% CI: 1.83 to 2.93; P < 0.001); the results for NCAE medications and falls were similar. Both polypharmacy and number of NCAE medications remained strongly and independently associated with falls in multivariable models adjusted for HIV serostatus, study site, sociodemographics, clinical characteristics, and substance use. CONCLUSIONS: Polypharmacy and NCAE medication use were greater among WWH compared with HIV-, and both were independently and incrementally related to falls. Deprescribing and avoidance of medications with NCAEs may be an important consideration for reducing fall risk among WWH and sociodemographically similar women without HIV.
Authors: Meredith Greene; Kenneth E Covinsky; Victor Valcour; Yinghui Miao; Joy Madamba; Harry Lampiris; Irena Stijacic Cenzer; Jeffrey Martin; Steven G Deeks Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Ann Khalsa; Roksana Karim; Wendy J Mack; Howard Minkoff; Mardge Cohen; Mary Young; Kathryn Anastos; Phyllis C Tien; Eric Seaberg; Alexandra M Levine Journal: AIDS Date: 2007-11-30 Impact factor: 4.177
Authors: Anjali Sharma; Donald R Hoover; Qiuhu Shi; Susan Holman; Michael W Plankey; Phyllis C Tien; Kathleen M Weber; Michelle Floris-Moore; Hector H Bolivar; David E Vance; Elizabeth T Golub; Marcia McDonnell Holstad; Michael T Yin Journal: Antivir Ther Date: 2018 Impact factor: 1.679
Authors: Leah H Rubin; Pauline M Maki; Gayle Springer; Lorie Benning; Kathryn Anastos; Deborah Gustafson; Maria C Villacres; Xiong Jiang; Adaora A Adimora; Drenna Waldrop-Valverde; David E Vance; Hector Bolivar; Christine Alden; Eileen M Martin; Victor G Valcour Journal: Neurology Date: 2017-09-13 Impact factor: 9.910